Positive outcome in a high-grade myxofibrosarcoma: a case report

1. DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg’s cancer: Principles & practice of oncology. 10th ed., 2014, United States: Lippincott Williams and Wilkins, 1540.Search in Google Scholar

2. Mentzel T, van den Berg E, Molenaar W. Myxofibrosarcoma. In: Fletcher C, Unni K, Mertens F. WHO classification of tumors - pathology and genetics, tumors of soft tissue and bone. 2002, Lyon: IARC Press, 102-1031.Search in Google Scholar

3. Castro BAC, Piancastelli ACC, Meyer RLB, Piancastelli PM, Ribeiro CA, Miranda RMC. Myxofibrosarcoma - Case report. 2016; 91(1):97-9.10.1590/abd1806-4841.20163922Search in Google Scholar

4. Dodd LG, Bui MM. Atlas of Soft Tissue and Bone Pathology: With Histologic, Cytologic, and Radiologic Correlations. 2015, New York: Demos Medical, 68-71.Search in Google Scholar

5. Schepper AM, Vanhoenacker F, Gielen J, Parizel PM. Imaging of soft tissue tumors. 3. 2006, Berlin Heidelberg New York: Springer-Verlag, 196-198.10.1007/3-540-30792-3Search in Google Scholar

6. Mentzel T, Calonje E, Wadden C, Camplejohn RS, Beham A, Smith MA, Fletcher CD. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J SurgPathol. 1996; 20:391-405.10.1097/00000478-199604000-00001Search in Google Scholar

7. Merck C, Angervall L, Kindblom LG, Oden A. Myxofibrosarcoma. A malignant soft tissue tumor of fibroblastichistiocytic origin. A clinicopathologic and prognostic study of 110 cases using multivariate analysis. Acta PatholMicrobiol Immunol Scand. 1953; Suppl 282:1-40.Search in Google Scholar

8. Weiss SW, Enzinger FM. Myxoid variant of malignant fibrous histiocytoma. Cancer. 1977; 39:1672-1685.10.1002/1097-0142(197704)39:4<1672::AID-CNCR2820390442>3.0.CO;2-CSearch in Google Scholar

9. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997; 350:1647–54.10.1016/S0140-6736(97)08165-8Search in Google Scholar

10. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. ClinOrthopRelat Res. 1980; 153:106-120.10.1097/00003086-198011000-00013Search in Google Scholar

11. Smolle MA, Dimosthenis A, Per-Ulf T, Szkandera J, Liegl-Atzwanger B, Leithner A. Diagnosis and treatment of soft-tissue sarcomas of the extremities and trunk. EFORT Open Rev. 2017; 2:421-431.10.1302/2058-5241.2.170005Search in Google Scholar

12. The ESMO/ European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2014; 25:iii102-iii112.10.1093/annonc/mdu254Search in Google Scholar

13. Judson I, Verweij J, Gelderblom H et al. European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupDoxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014; 15:415-423.10.1016/S1470-2045(14)70063-4Open DOISearch in Google Scholar

14. Antman K, Crowley J, Balcerzak SP et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J ClinOncol. 1993; 11:1276-1285.10.1200/JCO.1993.11.7.1276Search in Google Scholar